Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding Using Hybrid Neurosurgery Platform Multicenter Study to Improve Emergency Care and Outcomes

What this Trial Is About

This research focuses on patients with acute cerebral arteriovenous malformation AVM bleeding, a leading cause of brain hemorrhage in young adults characterized by sudden onset and rapid progression. The study evaluates the use of a hybrid neurosurgical operating room that combines neurointervention and microneurosurgery to improve emergency treatment for cerebral AVM-related hemorrhage. Through a multicenter, prospective, registry-based approach, the study aims to establish standardized protocols and workflows for this emergency treatment. Participants admitted to the hybrid operating room first undergo emergency cerebral angiography to confirm diagnosis. If suitable for surgery, they receive one-stop composite surgery, which may include neurointerventional embolization, microsurgical removal of the vascular malformation, or minimally invasive hematoma evacuation. The treatment plan is tailored during surgery based on the characteristics of the malformation, and intraoperative ultrasound helps locate the lesion and assess removal completeness. Head digital subtraction angiography DSA is reviewed immediately after surgery to confirm treatment success or determine further intervention. Participants are monitored with neurological outcome assessments at 2 weeks, 3 months, and 6 months after surgery. Surgical information and any complications are collected before, during, and shortly after surgery, as well as during follow-up visits. The study aims to improve patient outcomes while reducing medical costs and societal burdens by continuously enhancing the quality of emergency AVM hemorrhage management using the hybrid neurosurgical platform. The total study duration includes these follow-up periods to comprehensively evaluate treatment impact.

Clinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding